Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| UroGen Pharma Ltd.URGN · Entity 4466 | General Counsel | September 07, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
UroGen Pharma Ltd.
Report date September 07, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 53,141 |
Ending reported balance
After 2026-09-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-07 · Exercise / conversion · Acquired 3,334 · Balance 54,660 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Row 2 · 2026-09-08 · Sale · Disposed 1,519 · Balance 53,141 F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-09-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-07 · Exercise / conversion · Disposed 3,334 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3: The reporting person was granted RSUs on September 7, 2023 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
F3: The reporting person was granted RSUs on September 7, 2023 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2026 Filed Sep 9, 2026 18:35 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 1,519 | $42.54 | $64,618.26 |
DisclosureSEC source: 0001437749-26-029963 · rdgdoc.xml · nonDerivative · entry 2 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,141 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| September 07, 2026 Filed Sep 9, 2026 18:35 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 3,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-029963 · rdgdoc.xml · derivative · entry 3 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted RSUs on September 7, 2023 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024. F3 · derivative.expiration_date: The reporting person was granted RSUs on September 7, 2023 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024. Read SEC document |
| September 07, 2026 Filed Sep 9, 2026 18:35 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 3,334 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-26-029963 · rdgdoc.xml · nonDerivative · entry 1 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,660 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| February 03, 2026 Filed Feb 11, 2026 19:54 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 3,217 | $19.69 | $63,342.73 |
DisclosureSEC source: 0001437749-26-003778 · rdgdoc.xml · nonDerivative · entry 6 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,588 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| February 03, 2026 Filed Feb 11, 2026 19:54 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 1,608 | $19.69 | $31,661.52 |
DisclosureSEC source: 0001437749-26-003778 · rdgdoc.xml · nonDerivative · entry 4 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,326 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| February 03, 2026 Filed Feb 11, 2026 19:54 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 2,654 | $19.69 | $52,257.26 |
DisclosureSEC source: 0001437749-26-003778 · rdgdoc.xml · nonDerivative · entry 2 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,934 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| January 31, 2026 Filed Feb 11, 2026 19:54 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantRestricted Stock Units · Derivative | 32,609 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-003778 · rdgdoc.xml · derivative · entry 10 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,609 Underlying: Ordinary Shares · 32,609 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F6 · derivative.exercise_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2027, January 31, 2028 and January 31, 2029. F6 · derivative.expiration_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2027, January 31, 2028 and January 31, 2029. Read SEC document |
| January 31, 2026 Filed Feb 11, 2026 19:54 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 6,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-003778 · rdgdoc.xml · derivative · entry 9 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F4 · derivative.exercise_date: The reporting person was granted RSUs on January 31, 2023 representing 20,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2024. F4 · derivative.expiration_date: The reporting person was granted RSUs on January 31, 2023 representing 20,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2024. Read SEC document |
| January 31, 2026 Filed Feb 11, 2026 19:54 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 3,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-003778 · rdgdoc.xml · derivative · entry 8 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,667 Underlying: Ordinary Shares · 3,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted RSUs on January 31, 2025 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2026. F3 · derivative.expiration_date: The reporting person was granted RSUs on January 31, 2025 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2026. Read SEC document |
| January 31, 2026 Filed Feb 11, 2026 19:54 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-003778 · rdgdoc.xml · derivative · entry 7 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,500 Underlying: Ordinary Shares · 5,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F5 · derivative.exercise_date: The reporting person was granted RSUs on January 31, 2024 representing 16,500 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2025. F5 · derivative.expiration_date: The reporting person was granted RSUs on January 31, 2024 representing 16,500 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2025. Read SEC document |
| January 31, 2026 Filed Feb 11, 2026 19:54 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 6,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-26-003778 · rdgdoc.xml · nonDerivative · entry 5 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 31, 2026 Filed Feb 11, 2026 19:54 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 3,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-26-003778 · rdgdoc.xml · nonDerivative · entry 3 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 31, 2026 Filed Feb 11, 2026 19:54 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 5,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-26-003778 · rdgdoc.xml · nonDerivative · entry 1 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,472 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| September 08, 2025 Filed Sep 9, 2025 22:32 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 1,520 | $19.11 | $29,047.20 |
DisclosureSEC source: 0001437749-25-028705 · rdgdoc.xml · nonDerivative · entry 2 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,305 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| September 07, 2025 Filed Sep 9, 2025 22:32 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 3,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-028705 · rdgdoc.xml · derivative · entry 3 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,334 Underlying: Ordinary Shares · 3,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted RSUs on September 7, 2023 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024. F3 · derivative.expiration_date: The reporting person was granted RSUs on September 7, 2023 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024. Read SEC document |
| September 07, 2025 Filed Sep 9, 2025 22:32 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 3,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-028705 · rdgdoc.xml · nonDerivative · entry 1 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| July 28, 2025 Filed Jul 30, 2025 20:03 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 7,522 | $19.14 | $143,971.08 |
DisclosureSEC source: 0001437749-25-023963 · rdgdoc.xml · nonDerivative · entry 2 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,492 F3 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of performance stock units. Read SEC document |
| July 28, 2025 Filed Jul 30, 2025 20:03 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 16,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-023963 · rdgdoc.xml · nonDerivative · entry 1 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the settlement of performance stock units granted on January 31, 2024 that vested upon the achievement of a corporate milestone event. F2 · price: Each performance stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 16:51 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-002685 · rdgdoc.xml · derivative · entry 10 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F6 · derivative.exercise_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2026, January 31, 2027 and January 31, 2028. F6 · derivative.expiration_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2026, January 31, 2027 and January 31, 2028. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 16:51 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-002685 · rdgdoc.xml · derivative · entry 9 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Underlying: Ordinary Shares · 5,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F5 · derivative.exercise_date: The reporting person was granted RSUs on January 31, 2024 representing 16,500 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2025. F5 · derivative.expiration_date: The reporting person was granted RSUs on January 31, 2024 representing 16,500 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2025. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 16:51 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 6,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-002685 · rdgdoc.xml · derivative · entry 8 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,667 Underlying: Ordinary Shares · 6,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F4 · derivative.exercise_date: The reporting person was granted RSUs on January 31, 2023 representing 20,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2024. F4 · derivative.expiration_date: The reporting person was granted RSUs on January 31, 2023 representing 20,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2024. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 16:51 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-002685 · rdgdoc.xml · derivative · entry 7 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted RSUs on January 31, 2022 representing 7,500 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2023. F3 · derivative.expiration_date: The reporting person was granted RSUs on January 31, 2022 representing 7,500 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2023. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 16:51 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 2,767 | $11.14 | $30,824.38 |
DisclosureSEC source: 0001437749-25-002685 · rdgdoc.xml · nonDerivative · entry 6 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,514 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 16:51 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 5,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-002685 · rdgdoc.xml · nonDerivative · entry 5 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,281 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 16:51 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 3,354 | $11.14 | $37,363.56 |
DisclosureSEC source: 0001437749-25-002685 · rdgdoc.xml · nonDerivative · entry 4 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,781 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 16:51 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 6,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-002685 · rdgdoc.xml · nonDerivative · entry 3 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,135 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 16:51 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 1,258 | $11.14 | $14,014.12 |
DisclosureSEC source: 0001437749-25-002685 · rdgdoc.xml · nonDerivative · entry 2 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,468 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 16:51 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 2,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-002685 · rdgdoc.xml · nonDerivative · entry 1 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,726 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| September 09, 2024 Filed Sep 12, 2024 17:51 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 3,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-029038 · rdgdoc.xml · derivative · entry 3 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,667 Underlying: Ordinary Shares · 3,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted RSUs on September 7, 2023 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024. F3 · derivative.expiration_date: The reporting person was granted RSUs on September 7, 2023 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024. Read SEC document |
| September 09, 2024 Filed Sep 12, 2024 17:51 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 1,521 | $13.08 | $19,894.68 |
DisclosureSEC source: 0001437749-24-029038 · rdgdoc.xml · nonDerivative · entry 2 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,226 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| September 09, 2024 Filed Sep 12, 2024 17:51 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 3,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-029038 · rdgdoc.xml · nonDerivative · entry 1 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,747 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 02:16 UTC Amendment | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 3,328 | $15.78 | $52,515.84 |
DisclosureSEC source: 0001437749-24-003155 · rdgdoc.xml · nonDerivative · entry 3 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,414 F1 · date: This amendment corrects and restates the date of sale reported in the original Form 4 filed on February 2, 2024. F2 · price: This amendment corrects and restates the sales price reported in the original Form 4 filed on February 2, 2024. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 02:16 UTC Amendment | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 1,248 | $15.78 | $19,693.44 |
DisclosureSEC source: 0001437749-24-003155 · rdgdoc.xml · nonDerivative · entry 2 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,076 F1 · date: This amendment corrects and restates the date of sale reported in the original Form 4 filed on February 2, 2024. F2 · price: This amendment corrects and restates the sales price reported in the original Form 4 filed on February 2, 2024. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 02:16 UTC Amendment | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 417 | $15.78 | $6,580.26 |
DisclosureSEC source: 0001437749-24-003155 · rdgdoc.xml · nonDerivative · entry 1 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,824 F1 · date: This amendment corrects and restates the date of sale reported in the original Form 4 filed on February 2, 2024. F2 · price: This amendment corrects and restates the sales price reported in the original Form 4 filed on February 2, 2024. Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 00:12 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantRestricted Stock Units · Derivative | 16,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-003018 · rdgdoc.xml · derivative · entry 10 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Ordinary Shares · 16,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F6 · derivative.exercise_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2025, January 31, 2026 and January 31, 2027. F6 · derivative.expiration_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2025, January 31, 2026 and January 31, 2027. Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 00:12 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 6,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-003018 · rdgdoc.xml · derivative · entry 9 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,334 Underlying: Ordinary Shares · 6,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F5 · derivative.exercise_date: The reporting person was granted RSUs on January 31, 2023 representing 20,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2024. F5 · derivative.expiration_date: The reporting person was granted RSUs on January 31, 2023 representing 20,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2024. Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 00:12 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-003018 · rdgdoc.xml · derivative · entry 8 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Underlying: Ordinary Shares · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F4 · derivative.exercise_date: The reporting person was granted RSUs on January 31, 2022 representing 7,500 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2023. F4 · derivative.expiration_date: The reporting person was granted RSUs on January 31, 2022 representing 7,500 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2023. Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 00:12 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 834 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-003018 · rdgdoc.xml · derivative · entry 7 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 834 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted RSUs on January 31, 2021 representing 2,500 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2022. F3 · derivative.expiration_date: The reporting person was granted RSUs on January 31, 2021 representing 2,500 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2022. Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 00:12 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 3,328 | $15.74 | $52,382.72 |
DisclosureSEC source: 0001437749-24-003018 · rdgdoc.xml · nonDerivative · entry 6 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,414 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 00:12 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 6,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-003018 · rdgdoc.xml · nonDerivative · entry 5 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,742 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 00:12 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 1,248 | $15.74 | $19,643.52 |
DisclosureSEC source: 0001437749-24-003018 · rdgdoc.xml · nonDerivative · entry 4 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,076 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 00:12 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 2,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-003018 · rdgdoc.xml · nonDerivative · entry 3 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 00:12 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 417 | $15.74 | $6,563.58 |
DisclosureSEC source: 0001437749-24-003018 · rdgdoc.xml · nonDerivative · entry 2 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,824 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 00:12 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 834 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-003018 · rdgdoc.xml · nonDerivative · entry 1 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,241 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| September 07, 2023 Filed Sep 8, 2023 19:41 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-025479 · rdgdoc.xml · derivative · entry 1 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F2 · derivative.exercise_date: 1/3 of the shares underlying the restricted stock units will vest on each of September 7, 2024, September 7, 2025 and September 7, 2026 F2 · derivative.expiration_date: 1/3 of the shares underlying the restricted stock units will vest on each of September 7, 2024, September 7, 2025 and September 7, 2026 Read SEC document |
| August 31, 2023 Filed Sep 5, 2023 20:28 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 8,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-025204 · rdgdoc.xml · derivative · entry 3 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted RSUs on August 31, 2020 representing 25,000 ordinary shares. The RSUs vested in three equal installments on November 30, 2021, August 31, 2022 and August 31, 2023. F3 · derivative.expiration_date: The reporting person was granted RSUs on August 31, 2020 representing 25,000 ordinary shares. The RSUs vested in three equal installments on November 30, 2021, August 31, 2022 and August 31, 2023. Read SEC document |
| August 31, 2023 Filed Sep 5, 2023 20:28 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 3,800 | $18.01 | $68,438.00 |
DisclosureSEC source: 0001437749-23-025204 · rdgdoc.xml · nonDerivative · entry 2 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,407 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| August 31, 2023 Filed Sep 5, 2023 20:28 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 8,334 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-025204 · rdgdoc.xml · nonDerivative · entry 1 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,207 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 18:04 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantEmployee Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $10.39 | $0.00 |
DisclosureSEC source: 0001437749-23-002338 · rdgdoc.xml · derivative · entry 8 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Ordinary Shares · 40,000 shares Expires 2033-01-31 F6 · derivative.exercise_date: 1/3 of the shares underlying the stock options will vest on each of January 31, 2024, January 31, 2025 and January 31, 2026. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 18:04 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-002338 · rdgdoc.xml · derivative · entry 7 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Ordinary Shares · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F5 · derivative.exercise_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2024, January 31, 2025 and January 31, 2026. F5 · derivative.expiration_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2024, January 31, 2025 and January 31, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.